Total
0
Shares
Telix Pharmaceuticals (ASX:TLX)- CEO, Dr. Christian Behrenbruch - The Market Herald
CEO, Dr. Christian Behrenbruch
Source: Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Telix Pharmaceuticals (TLX) has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its prostate cancer imaging product, TLX591-CDx
  • Telix's new drug application includes clinical data compiled from over 600 patients
  • The company has been working with the FDA since July 2019 to help submit a comprehensive application
  • CEO Dr Christian Behrenbruch said submitting an NDA to the FDA is a major commercial inflection point for the company
  • Telix ended the day up a slight 0.85 per cent to trade for $1.78

Telix Pharmaceuticals (TLX) has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its prostate cancer imaging product, TLX591-CDx.

TLX591-CDx technology targets Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography.

Telix's NDA submission includes the clinical data from over 600 patients from clinical studies.

President for the U.S. branch, Dr Bernard Lambert, is happy with this milestone as it marks the company's first commercial NDA for PSMA imaging in the U.S.

"Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission. Subject to FDA approval, we
look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer," he said.

CEO Dr Christian Behrenbruch said submitting an NDA to the FDA is a major commercial inflection point for the company and follows the European submission earlier this year.

"The Telix team and our advisors have done an outstanding job of preparing this submission, which we believe is founded on compelling clinical evidence that supports broad diagnostic utility in the management of prostate cancer," he said.

"I’d like to acknowledge the commitment of our investigators, study teams and the independent physician readers who contributed to our clinical data package," he added.

On the market this afternoon, Telix is up 0.71 per cent and is trading for $1.77 per share at 3:58 pm AEST.

TLX by the numbers
More From The Market Herald
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong (centre-left) - The Market Herald

" Imugene (ASX:IMU) increases loss, ramps up trials and research

Imugene (IMU) has ended the half-year with a $6 million loss after increasing its spending on clinical trials and research.
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) pockets $830K R&D rebate

Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive.
Palla Pharma (ASX:PAL) - Departing CEO, Jarrod Ritchie - The Market Herald

" Palla Pharma (ASX:PAL) to raise $18M to reduce debt

Palla Pharma (PAL) has announced plans to tap investors and shareholders for an extra $18 million in capital via a fundraise.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) declares outstanding half-year revenue growth

Incannex Healthcare (IHL) has reported a revenue growth of 11,859 per cent to $1.23 million for the six months to December 31, 2020.